» Articles » PMID: 36262151

Heterogeneous Network Propagation with Forward Similarity Integration to Enhance Drug-target Association Prediction

Overview
Date 2022 Oct 20
PMID 36262151
Authors
Affiliations
Soon will be listed here.
Abstract

Identification of drug-target interaction (DTI) is a crucial step to reduce time and cost in the drug discovery and development process. Since various biological data are publicly available, DTIs have been identified computationally. To predict DTIs, most existing methods focus on a single similarity measure of drugs and target proteins, whereas some recent methods integrate a particular set of drug and target similarity measures by a single integration function. Therefore, many DTIs are still missing. In this study, we propose heterogeneous network propagation with the forward similarity integration (FSI) algorithm, which systematically selects the optimal integration of multiple similarity measures of drugs and target proteins. Seven drug-drug and nine target-target similarity measures are applied with four distinct integration methods to finally create an optimal heterogeneous network model. Consequently, the optimal model uses the target similarity based on protein sequences and the fused drug similarity, which combines the similarity measures based on chemical structures, the Jaccard scores of drug-disease associations, and the cosine scores of drug-drug interactions. With an accuracy of 99.8%, this model significantly outperforms others that utilize different similarity measures of drugs and target proteins. In addition, the validation of the DTI predictions of this model demonstrates the ability of our method to discover missing potential DTIs.

Citing Articles

DTI-MHAPR: optimized drug-target interaction prediction via PCA-enhanced features and heterogeneous graph attention networks.

Yang G, Liu Y, Wen S, Chen W, Zhu X, Wang Y BMC Bioinformatics. 2025; 26(1):11.

PMID: 39800678 PMC: 11726937. DOI: 10.1186/s12859-024-06021-z.

References
1.
Damaj M, Flood P, Ho K, May E, Martin B . Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2004; 312(2):780-5. DOI: 10.1124/jpet.104.075093. View

2.
Suratanee A, Plaimas K . Reverse Nearest Neighbor Search on a Protein-Protein Interaction Network to Infer Protein-Disease Associations. Bioinform Biol Insights. 2017; 11:1177932217720405. PMC: 5513527. DOI: 10.1177/1177932217720405. View

3.
KOYUNCUOGLU H, Saydam B . The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther Toxicol. 1990; 28(4):147-52. View

4.
Steensland P, Simms J, Holgate J, Richards J, Bartlett S . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007; 104(30):12518-23. PMC: 1914040. DOI: 10.1073/pnas.0705368104. View

5.
Jarada T, Rokne J, Alhajj R . SNF-NN: computational method to predict drug-disease interactions using similarity network fusion and neural networks. BMC Bioinformatics. 2021; 22(1):28. PMC: 7821180. DOI: 10.1186/s12859-020-03950-3. View